Citius Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 12, 2024, reports the closing of a previously announced merger and reorganization involving Citius Pharmaceuticals, Inc. ("Citius Pharma") and its wholly owned subsidiary, Citius Oncology, Inc. ("SpinCo"). On this date, SpinCo merged with TenX Merger Sub Inc., a subsidiary of TenX Keane Acquisition ("TenX"). TenX subsequently domesticated as a Delaware corporation and changed its name to "Citius Oncology, Inc." Immediately following the closing, Citius Pharma owns approximately 92.6% of the outstanding common stock of the newly named Citius Oncology.
Key Financial Metrics and Obligations
The filing details specific financial transactions and obligations arising from the merger closing:
- Capital Contribution: Citius Pharma contributed $10,000,000 in cash to the Company. This amount was allocated as follows: $3,800,111 for working capital, $6,199,889 for transaction expenses, and $1,077,026 for the purchase of TenX rights (which converted into 422,353 shares of Citius Oncology common stock).
- Promissory Note: Citius Oncology issued a non-interest-bearing promissory note to Citius Pharma for $3,800,111 to cover operating expenses and working capital. Repayment is due in full upon Citius Oncology securing a financing of at least $10 million.
- Registration Rights: An aggregate of 65,627,262 shares of Citius Oncology held by Citius Pharma are covered under an Amended and Restated Registration Rights Agreement.
The filing does not provide revenue, profit, cash flow, or margin data for the reporting period.
Material Changes and Agreements
Several material agreements were executed or amended on August 12, 2024:
- Shared Services Agreement: An amended and restated agreement governs management and scientific services provided by Citius Pharma to Citius Oncology, similar to the pre-closing arrangement.
- Registration Rights: Holders of Registrable Securities are entitled to up to three demand registrations. Citius Oncology agreed to use commercially reasonable efforts to file a registration statement for resale within 120 days of the agreement date.
- Transfer Restrictions: The Sponsor and Citius Pharma are restricted from transferring shares for six months post-closing, unless the share price exceeds $12.00 for 20 trading days within a 30-day period or a change of control transaction occurs.
- Waivers: A Letter Agreement waived certain closing conditions, including the immediate transfer of the LYMPHIRTM trademark and FDA notification regarding BLA/IND ownership rights. These transfers are now scheduled to occur within 60 days following the closing.
Outlook, Risks, and Contingencies
The filing indicates that the repayment of the $3.8 million promissory note is contingent upon Citius Oncology completing a financing of at least $10 million. The company has entered into customary registration rights agreements which may impact future capital raising activities. No specific forward-looking guidance regarding revenue or clinical milestones is provided in this specific filing text.
Key Facts for Investor Verification
- Verify the current ownership percentage of Citius Pharma in Citius Oncology (stated as approx. 92.6% post-closing).
- Confirm the status of the $10 million financing required to trigger repayment of the $3.8 million promissory note.
- Monitor the timeline for the transfer of the LYMPHIRTM trademark and FDA notifications, now extended to 60 days post-closing.
- Review the terms of the Amended and Restated Registration Rights Agreement regarding the 65.6 million shares held by Citius Pharma.
- Check for any press releases or subsequent filings regarding the $12.00 per share price threshold that would lift transfer restrictions.